RFA-HG-22-008 - Multi-Omics for Health and Disease - Disease Study Sites (U01 Clinical Trial Optional)
RFA-HG-22-009 - Multi-Omics for Health and Disease - 'Omics Production Centers (U01 Clinical Trial Not Allowed)
RFA-HG-22-010 -Multi-Omics for Health and Disease - Data Analysis and Coordination Center (U01 Clinical Trial Not Allowed)
NOT-HG-23-006 - Notice of Change in the Number of Disease Study Sites (DSSs) in RFA-HG-22-008 “Multi-Omics for Health and Disease - Disease Study Sites (U01 Clinical Trial Optional)”
NOT-HG-23-008 - Notice of Change in the Number of Disease Study Sites (DSSs) in RFA-HG-22-010 “Multi-Omics for Health and Disease - Data Analysis and Coordination Center (U01 Clinical Trial Not Allowed)”
National Human Genome Research Institute (NHGRI)
The “Multi-Omics for Health and Disease Consortium” is a consortium involving three related RFAs (RFA-HG-22-008, RFA-HG-22-009, and RFA-HG-22-010). The purpose of this Notice is to correct the number of DSSs in RFA-HG-22-009 “Multi-Omics for Health and Disease - 'Omics Production Centers (U01 Clinical Trial Not Allowed)” that will be funded as part of the Multi-Omics for Health and Disease Consortium. The following two subsections of Part 2. Section I. -- "Background and Objectives" and “Research Approach” -- have been edited (in bold italics). The number of Disease Study Sites (DSSs) in RFA-HG-22-008 and RFA-HG-22-010 will be corrected in separate Notices (NOT-HG-23-006 and NOT-HG-23-008, respectively).
Answers to questions discussed during the recently held pre-application webinar, as well as the webinar recording and slides, are available at: https://www.genome.gov/event-calendar/pre-applicant-webinar-for-multi-omics-for-health-and-disease-consortium. They further clarify the number of DSSs and provide additional details about the Consortium, including questions around the budget and sample size.
Currently reads
Part 2. Full Text of Announcement
Section I. Funding Opportunity Description
Background and Objectives (Paragraph #5)
This FOA solicits applications to establish the OPC(s).RFA-HG-22-008 and RFA-HG-22-010 will establish 4 DSSs and the DACC, respectively.
Research Approach (Paragraph #7)
The NIH anticipates funding 4 DSSs. Each one will be responsible for the enrollment of 300 participants, approximately 200 with disease and 100 without disease. All phenotypic and environmental exposure data, as defined above, will be collected by the DSSs. The biosamples collected by the DSS will be submitted to the OPC(s) for processing and for production of ‘omics data types. The OPC(s) will utilize state-of-the art high-throughput molecular assays to rapidly identify and quantify different ‘omic data from the biosamples provided by the DSSs. The OPC(s) are expected to produce all the molecular data for this program.
Modified to read
Part 2. Full Text of Announcement
Section I. Funding Opportunity Description
Background and Objectives (Paragraph #5)
This FOA solicits applications to establish the OPC(s).RFA-HG-22-008 and RFA-HG-22-010 will establish up to 6 DSSs and the DACC, respectively.
Research Approach (Paragraph #7)
The NIH anticipates funding up to 6 DSSs. Each one will be responsible for the enrollment of 300 participants, approximately 200 with disease and 100 without disease. All phenotypic and environmental exposure data, as defined above, will be collected by the DSSs. The biosamples collected by the DSS will be submitted to the OPC(s) for processing and for production of ‘omics data types. The OPC(s) will utilize state-of-the art high-throughput molecular assays to rapidly identify and quantify different ‘omic data from the biosamples provided by the DSSs. The OPC(s) are expected to produce all the molecular data for this program.
All other aspects of the FOA remain unchanged.
Please direct all inquiries to:
Joannella Morales, Ph.D.
National Human Genome Research Institute (NHGRI)
Email: [email protected]
and Human Services (HHS)
